Skip to main content

Advertisement

SpringerLink
Log in

A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jansen K, Heirbaut L, Verkerk R, et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J Med Chem. 2014;57(7):3053–74.

    Article  CAS  Google Scholar 

  2. Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.

    Article  CAS  Google Scholar 

  3. Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.

    Article  CAS  Google Scholar 

  4. Moon ES, Elvas F, Vliegen G, De Lombaerde S, et al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. EJNMMI Radiopharm Chem. 2020:submitted.

  5. Lindner T, Loktev A, Giesel F, et al. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm Chem. 2019;4:16.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Sanjana Ballal and Madhav Prasad Yadav contributed equally to this work.

Authors and Affiliations

  1. Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India

    Sanjana Ballal, Madhav Prasad Yadav, Madhav Tripathi, Sreedharan Thankarajan ArunRaj & Chandrasekhar Bal

  2. PositronPharma SA, Santiago, Chile

    Vasko Kramer

  3. Department of Chemistry, Johannes Gutenberg University, Mainz, Germany

    Euy Sung Moon & Frank Roesch

  4. Department of Pathology, All India Institute of Medical Sciences, New Delhi, 110029, India

    Soumyaranjan Mallick

Authors
  1. Sanjana Ballal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madhav Prasad Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vasko Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Euy Sung Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frank Roesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Madhav Tripathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Soumyaranjan Mallick
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sreedharan Thankarajan ArunRaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chandrasekhar Bal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chandrasekhar Bal.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical clearance

Ref. No IECPG-22/2020 for the clinical use of [68Ga]Ga-DOTA.SA.FAPi and Ref. No. IEC/1054/5/2020 for the clinical use of [177Lu]Lu-DOTA.SA.FAPi.

Informed consent

Written informed consent from the patient was obtained before the conduction of imaging and therapy.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The current work has not been submitted for review or has not been accepted in any journal.

This article is part of the Topical Collection on Image of the month

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ballal, S., Yadav, M.P., Kramer, V. et al. A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 48, 942–944 (2021). https://doi.org/10.1007/s00259-020-04990-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-020-04990-w

Search

Navigation